Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1373 ARTÍCULOS , VIENDO DEL 1006 AL 1020

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2013 Dec;74(6):826-36. doi: 10.1002/ana.23908.

Machine learning and social network analysis applied to Alzheimer's disease biomarkers

Di Deco J, González AM, Díaz J, Mato V, García-Frank D, Álvarez-Linera J, Frank A, Hernández-Tamames JA.

Curr Top Med Chem. 2013;13(5):652-62. doi: 10.2174/1568026611313050008.

Effect of cognitive reserve markers on Alzheimer pathologic progression

Lo RY, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):343-50. doi: 10.1097/WAD.0b013e3182900b2b.

Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria

Sperling R, Johnson K.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):325-38. doi: 10.1212/01.CON.0000429181.60095.99.

BIN1 gene rs744373 polymorphism contributes to Alzheimer's disease in East Asian population

Liu G, Zhang S, Cai Z, Li Y, Cui L, Ma G, Jiang Y, Zhang L, Feng R, Liao M, Chen Z, Zhao B, Li K.

Neurosci Lett. 2013 Jun 7;544:47-51. doi: 10.1016/j.neulet.2013.02.075. Epub 2013 Apr 6.

Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process

Stefani A, Olivola E, Stampanoni Bassi M, Pisani V, Imbriani P, Pisani A, Pierantozzi M.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):538-46. doi: 10.2174/1871527311312040016.

Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease

Tiedt HO, Lueschow A, Winter P, Müller U.

Neurosci Lett. 2013 Jun 7;544:115-8. doi: 10.1016/j.neulet.2013.03.056. Epub 2013 Apr 10.

Smell identification function as a severity and progression marker in Alzheimer's disease

Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S.

Int Psychogeriatr. 2013 Jul;25(7):1157-66. doi: 10.1017/S1041610213000446. Epub 2013 Apr 19.

[New risk genes for Alzheimer's disease--biomarkers predicting the disease?]

Hiltunen M, Haapasalo A, Soininen H.

Duodecim. 2013;129(6):583-8.

Alzheimer's disease biomarkers: correspondence between human studies and animal models

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Dis. 2013 Aug;56:116-30. doi: 10.1016/j.nbd.2013.04.010. Epub 2013 Apr 28.

Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease

Schmitt A, Falkai P.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):271-2. doi: 10.1007/s00406-013-0409-0.

Cerebrospinal fluid levels of phosphorylated tau and Aβ1-38/Aβ1-40/Aβ1-42 in Alzheimer's disease with PS1 mutations

Ikeda M, Yonemura K, Kakuda S, Tashiro Y, Fujita Y, Takai E, Hashimoto Y, Makioka K, Furuta N, Ishiguro K, Maruki R, Yoshida J, Miyaguchi O, Tsukie T, Kuwano R, Yamazaki T, Yamaguchi H, Amari M, Takatama M, Harigaya Y, Okamoto K.

Amyloid. 2013 Jun;20(2):107-12. doi: 10.3109/13506129.2013.790810. Epub 2013 May 2.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1.

Clinical trials in predementia stages of Alzheimer disease

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.

Applying the IWG research criteria in clinical practice: feasibility and ethical issues

Molinuevo JL, Rami L.

Med Clin North Am. 2013 May;97(3):477-84. doi: 10.1016/j.mcna.2012.12.018. Epub 2013 Feb 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias